reintroduc dose foresight disciplin sustain
canadian spec pharma
initi coverag knight therapeut inc outperform rate
target price knight early-stag specialti pharmaceut compani
spun paladin lab result acquisit endo intern
paladin knight ceo jonathan ross goodman develop consist track
record deliv war chest cash dispos believ time
knight outperform accomplish paladin uncov valu
patienc opportun calcul foresight
undeni strongest manag canadian spec pharma
ms khouri well known canada deliv spectacular exit
paladin lab acquisit endo intern furthermor paladin
histori manag prove time time steadfast commit deliv
sharehold valu respons disciplin capit deploy aim
gener futur growth bottom line profit
ampl strateg deploy current exit mln
cash market secur mln uncommit capit knight
possess
canadian specialti
pharmaceut peer believ knight best-posit compani
rapidli close uniqu transact opportun without caveat condit
alway focus bottom line still earli day amass
robust pipelin commerci therapeut diagnost asset knight
nonetheless gener approxim mln net incom sinc incept
uniqu lend invest strategi conjunct earli
would typic valu specialti pharmaceut compani util either
dcf valuat methodolog forward ebitda multipl believ neither approach
accur captur inher valu knight early-stag oper strategi
grow cash balanc particularli true present major knight
earn date gener interest incom loan receiv well
uniqu invest tactic opt util price-to-book valu per
share multipl valuat methodolog believ precis repres
current valu knight grow asset base specif valu knight
p/bvp repres discount north american specialti
comp current trade averag multipl result valu
per share round valuat section
publish
juli edt
compani report initi coverag
total return target
focus acquir
knight inc specialti pharmaceut
licens sell market prescript
born paladin lab result
acquisit
pleas read domest foreign disclosure/risk inform begin page analyst certif page
canada research page
tabl content
appendix manag board director
canada research page
mr goodman found paladin lab led compani year record
growth achiev revenu greater mln ebitda excess mln
sold per share bln foresight negoti
equiti endo part sale upon close transact deal effect
appreci valu bln goodman famili own paladin thu
view mr goodman motiv knight monetarili focus rather believ
sincer driven demonstr abil succeed think uniqu
unwav drive ensur knight victori
knight manag specif mr goodman ms sakhia ms khouri paladin
develop reput fight shoulder-to-should investor look
financi interest dedic sharehold transfer knight day
negoti everi sharehold paladin would receiv one common share knight
part transact furthermor date knight rais mln equiti capit five
separ financ round increas valuat signific particip
knight ceo current largest sharehold greater mln
cash market secur mln uncommit capit think knight undeni
best-posit specialti pharmaceut compani canada rapidli transact uniqu
paladin produc stagger return year per share easili
outperform tsx composit index period unapprov
post-coit contracept acquir paladin becam one paladin top-sel
product impavido acquir paladin result greater roi
knight sold prioriti review voucher prv issu connect fda
approv endo ascrib valu prv previou negoti type
transact come expect knight manag track record
lead us believ knight deploy capit time disciplin creativ
manner knight essenti tabula rasa at-risk cash flow recent opaqu
acquisit need conceal subsequ transact knight
extrem well-capit balanc sheet debt manag guid unlik
ever take debt believ begun set foundat rich pipelin
canada research page
specialti pharmaceut becom dirti phrase canada
investor follow canadian specialti pharmaceut industri past
year like pick consist theme specif canadian specialti pharmaceut
went period major compani subscrib multipl
accretion/financi arbitrag model acquir legaci asset perform life cycl
manag view model defin pharma model
realiti frequent fail result sustain model lucr
pharmaceut bull market strategi rapidli come pressur cycl
turn cost capit rise transact cadenc slow compani valuat compress
cycl turn investor expos signific downsid risk
opinion success specialti pharmaceut model defin full
cycl pharma model one requir abil gener volume-driven growth ii
respons use leverag iii strong manag iv disciplin use capit typic
full-cycl pharma model compani focu specialti therapeut nich larg
major prescrib physician call upon small special sale forc detail
product begin life cycl model compani benefit organ
volume- driven growth benefit signific oper leverag continu
build product portfolio view mr jonathan goodman knight ceo
founder wrote book full-cycl pharma model demonstr success
paladin lab model except rare replic canada subsequ
paladin believ mr goodman along ex-paladin team includ ms sakhia ms
khouri well way replic model knight therapeut
knight founder ceo jonathan ross goodman well known success
paladin lab howev mr goodman pharmaceut exposur preced paladin fact
eman long-stand pedigre canadian pharmaceut talent
mr goodman son pharmacist morri goodman began career
establish winley-morri compani focus seek distribut right
sever intern pharmaceut compani order bring product canada
subsequ becom canadian distributor l-dopa intern chemic nuclear
corpor icn icn purchas winley-morri establish morri goodman presid
mr morri goodman co-found pharmasci colleagu ted wise
pharmasci establish grown canada third-largest gener drug
compani annual sale excess mln mr jonathan goodman brother dr david
goodman current ceo pharmasci mr jonathan goodman join pharmasci
vice presid busi develop career junctur would ultim
catalyz pharmaceut legaci
path knighthood began paladin
paladin lab went public via rto geriatrx mr goodman presid ceo
incept paladin differenti typic canadian pharmaceut
compani focus free cash flow growth disciplin conserv manner
throughout year paladin oper independ revenu grew greater
mln ebitda exceed mln ep went loss per share gain
per share exhibit novemb announc endo enter
agreement acquir paladin lab per share bln share new
endo cash one share knight upon close deal februari
endo equiti valu significantli increas respons news particular
tax implic effect revalu transact bln per share
canada research page
paladin success direct result creativ insight disciplin use capit
gener distil follow capit deploy order acquir licens
product right ii high interest secur lend iii equiti invest strategi
enabl paladin establish reput gener industry-lead roi
throughout histori paladin grew niche-focus specialti pharmaceut compani
full-blown diversifi pharmaceut compani limit exposur singl product
time exit endo paladin amass portfolio consist greater activ
market product top per sale dexedrin tridur metadol pennsaid
 exhibit retrospect product signific growth potenti
acquir paladin key differenti strateg aspect rel mani acquisit observ
recent canadian specialti histori larg domin
multipl accret strategi buyer acquir support multipl mani case
acquir diminish cash flow astronom multipl view five product clearli
punctuat mr goodman foresight consid deploy capit strategi
reward patienc fundament theme report addit market product
paladin assembl growth pipelin consist development-stag
knowledg paladin longest pharmaceut amort period six year
impli manag reluct pay ebitda product
pharma remain activ divestitur non-cor asset note competit
landscap potenti buyer becom substanti crowd therefor
discount possibl knight may requir extend beyond histor upper rang
exhibit paladin lab top asset sale
addit product acquisit strategi paladin uniqu creat valu sharehold
acquir invest negoti secur loan variou healthcar compani
exampl march paladin purchas stake pharmaplan ltd
subsequ acquir litha healthcar group februari paladin exit
posit mln return similarli juli paladin purchas afexa
life scienc total consider approxim mln view acquir outright
develop cold-fx howev result bid war paladin
walk away final offer per share sell posit compani
mln octob return
productd acquired/ licensedvendor/targethistor sale sale mln cagrdexedrinenovemb june bdecemb capit corporationlaunch canada research page
begin econom downturn constrict access capit threaten
livelihood mani specul healthcar compani subsequ aftermath
paladin identifi opportun deploy capit opportunist low-risk manner
potenti attract return exampl decemb paladin mln
debt assign distress prostrakan along variou product right april
prostrakan acquir kyowa hakko kirin paladin repaid full furthermor
paladin receiv full year interest mln break fee retain aforement
product right paladin success replic creativ strategi numer occas
throughout lend averag rate exhibit
believ review signific valu manag clearli articul
intent creat paladin lab knight therapeut like follow
similar formula success
headquart montreal qc knight therapeut inc specialti pharmaceut compani
born busi separ agreement knight paladin lab knight began
oper februari day paladin sold endo importantli
consider paladin transact everi paladin sharehold receiv one share knight
paladin common share incept knight asset includ mln cash
world-wide right drug impavido partner paladin ex-u therapeut indic
treatment leishmaniasi knight began trade tsxv march
subsequ graduat tsx april
date knight success rais mln equiti capit five separ financ round
exhibit signific particip mr goodman increas
valuat mr goodman current largest sharehold knight ownership posit
march knight share outstand fd
manag adam knight mission becom paladin order
accomplish strategi fourfold plan licens innov pharmaceut
acquir matur under-promot product pharma develop near-term low-
risk/low-expens product canadian global market lend fulli secur
basi life scienc compani need interest and/or product right
datetypelendeeamount mln interest mln share issuedpricecommentsbrok bought deal full over-allot exercis bought deal upsiz mln bought deal upsiz mln full over-allot exercis bought deal full over-allot bought deal upsiz mln full over-allot exercis canada research page
build foundat growth
despit knight healthi balanc sheet thu abil execut acquisit product
portfolio current infanc attribut fact present environ
much seller market product fetch multipl exceed histor high note
similar market condit develop period throughout paladin lifespan earli
despit sharehold pressur paladin manag continu capit
deploy paladin resist instead opt remain disciplin retrospect paladin
disciplin paid price fell paladin one well-capit pharmaceut
compani abl execut opportunist significantli discount asset
look forward expect knight target three sourc new product specif non-cor
asset multi-national pharmaceut compani emerg specialti pharmaceut
compani lack canadian presenc biotechnolog compani product late-
stage clinic trial clinic development/risk perspect knight gener
consid product phase ii later date knight curat small assort
asset vari degre potenti exhibit follow text provid brief
review asset current approv current commerci
exhibit overview knight therapeut pipelin
dateproduct/familylicensor/vendorindicationregulatori statusterritori constipationmarket hyperphosphatemiaphas familyownedmigrain pain cnspre-clin phase isr ru famili antibechron pain inflammationpre-clin phase isr ru macular edemand inflammationnd diseasesphas pre-registrationcan isr familyadvaxishpv-associ oncolog othersphas phase peripher neuropath associ painmarket global ex familysynergyvari consum healthmarket isr rom ru bono bioosteoarthr associ pain/joint stiffnessnot marketedqc familycrescitadermo-cosmeticnot market isr rom ru ablationpivot trial signatur signaturestelomer imag base prognostics/diagnosticsdevelopmentcan isr rom ru zaflegend canada carribbean isr israel qc quebec rom romania ru russia zaf sub-saharan africapain/gi rx productsopthalm rx productsoth rx productsconsum productsmed device/diagnost product canada research page
movantik knight first commerci specialti product canada
decemb knight announc in-licens canadian isra right
movantik astrazeneca movantik naloxegol oxal therapeut indic
treatment opioid-induc constip adult patient non-canc pain
inadequ respons lax opioid-induc constip affect
patient take oral opioid
movantik current approv canada cover three patent expiri date
rang therapeut launch canada astrazeneca octob
relaunch knight march israel movantik current
regulatori review expect launch medison biotech movantik
sale canada period end octob forecast
movantik contribut approxim mln sale
februari knight announc enter sublicens agreement
braeburn pharmaceut inc wherebi knight receiv right commerci
probuphin canada product approv health canada april
probuphin subderm skin implant design deliv activ compound
buprenorphin continu six month follow singl treatment buprenorphin
activ ingredi suboxon subutex addit gener equival
consid signific new develop treatment opioid addict
buprenorphin suppress crave withdraw symptom enabl patient make long-
term behavior chang result sustain addict remiss current formul
buprenorphin plagu issu treatment divers miss dose abrupt
termin patient accident exposur non-pati accident overdos
probuphin provid solut issu promot complianc retent addit
prevent accident exposur
canada knight estim less addict specialist prescrib opioid
depend therapeut furthermor prescrib overlap call point
knight opioid support product movantik order estim peak annual
revenu knight canadian distribut probuphin take mean report
preval opioid depend canada individu estim rang
assum treatment cost per patient year line low rang end
averag per patient year treatment cost suboxon rang
pend dosag assum knight achiev peak penetr five year post
launch assum royalti braeburn revenu model suggest probuphin
could achiev peak annual revenu knight approxim mln exhibit
current forecast launch probuphin canada assum asset
contribut mln sale
amount preval opioid penetr number treat per patient gross royalti revenu knight therapeut inc
canada research page
juli knight announc sign exclus agreement inc
canadian distribut azasit
azasit durasit formul azithromycin broad spectrum ocular antibiot approv
us fda april health canada march indic treat bacteri
conjunct pink eye commerci us inspir pharmaceut inc
acquir right azasit merck
competit landscap consider popul key advantag azasit
reduc dose frequenc lead better complianc outcom ii lower
probabl bacteri resist base high tissu concentr azasit current
protect four patent expir current attribut valu azasit
model await guidanc knight regard launch time believ impend
gener entri may dissuad knight launch asset compani establish
ophthalmology-speci sale forc detail iluvian netildex azasit face gener
competit time commerci launch would estim revenu asset
believ manag strategi surround impavido perfectli highlight thesi
knight employ uniqu degre foresight consid potenti product acquisit
impavido miltefosin alkylphosphocholin fda-approv oral therapeut indic
treatment leishmaniasi leishmaniasi parasit diseas transmit certain type
sandfli endem tropic countri annual world-wide incid
approxim mln case diseas present either cutan mucocutan
impavido origin acquir paladin lab aeterna zentari mln trail
perpetu royalti time aeterna zentari activ divest asset
much-need inject capit paladin subsequ invest approxim mln
clinic develop therapeut intent posit fda approv us
approv therapi strateg decis paladin fda implement
prioriti review voucher prv program concept program incentiv drug
develop indic signific market specif rare pediatr
neglect tropic diseas upon approv therapeut fda grant transfer
voucher use expedit review time among margin benefit
subsequ potenti blockbust therapeut first-mov advantag could confer
negoti process paladin endo becam evid endo ascrib
valu prv could issu conjunct impavido us approv thu mr
goodman negoti transfer impavido ip right paladin lab sharehold via
format knight fda approv impavido march grant knight prv
novemb knight creat signific valu sharehold sold voucher
gilead mln valu doubl mln biomarin receiv voucher
arguabl valuabl voucher month prior sale regeneron
pharmaceut fact manag abl build compani around asset
preced valu spun paladin monet asset
twice recent establish preced speak volum manag foresight abil
execut view septemb knight announc enter
exclus distribut agreement profounda inc commerci impavido us
impavido offici launch us march
addit march knight announc reacquir world-wide right
impavido upon termin agreement paladin lab relat sale distribut
impavido paladin territori global ex-u result knight present distribut
impavido global sever intern distribut partner fulli recogn
impavido revenu oppos royalti origin paladin agreement
canada research page
model estim cumul annual revenu knight impavido sale approxim
mln annual exhibit specif viscer leishmaniasi take median
annual incid annual increas incid assum median
cost per patient cycl negoti cost per
cycl assum initi uptick market penetr driven
impavido avail us assum gross viscer sale deriv
profounda us sale knight receiv royalti
cutan leishmaniasi take median annual incid
annual increas incid assum median cost per patient per treatment
cycl negoti cost per cycl assum initi uptick market
penetr driven impavido avail us
assum gross cutan sale deriv profounda us sale knight
receiv royalti notabl believ potenti upsid estim off-
label usag us particularli primari ameb meningoenceph pam caus
naegleria fowleri infect ancanthamoeba kerat well companion pet usag
current valu off-label impavido use
exhibit histor forward impavido sale estim
neuragen gener valu worst-cas scenario
neuragen homeopath remedi market topic oil fast-act relief diabet
neuropathi product mixtur st john wort wolfban club moss rye ergot
proprietari blend geranium oil bergamot oil tea tree oil eucalyptu oil one small
manufacturer-fund studi publish demonstr efficaci pain reduct
trial view meet standard requir typic clinic program
requir regist prescript therapeut neuragen trial harbour number
limit make us somewhat skeptic actual clinic effect product
fact fda voic concern medic claim origin biom
make social media respect product nonetheless product licens
natur product canada
june knight acquir asset relat neuragen pursuant order
suprem court scotia follow default origin secur loan agreement
knight net asset acquir settl loan receiv
assign fair valu mln connect acquisit knight issu
warrant june origin stakehold exercis period year
exercis price per share per transact knight recogn gain settlement
loan receiv net relat expens
settlement june knight enter sale agreement
synergi strip relat us right neuragen would receiv minimum aggreg
consider mln mln maintain right asset canada
ex-u jurisdict april knight realiz valu asset
impavido revenu model leishmaniasisannu ww incid viscer penetr number treat per treat gross us revenu revenu leishmaniasisannu ww incid cutan penetr number treat per treat gross us revenu revenu impavido sale knight therapeut inc
canada research page
enter exclus distribut agreement empa healthcar llc commerci
neuragen unit arab emir kuwait detail empa transact
disclos believ up-front associ transact like materi
model assum nueragen contribut per year revenu knight
remain skeptic actual clinic util asset commerci longev natur
health product tend highli promot sensit subject fad effect
view ownership asset associ busi develop activ follow
acquisit prime exampl knight abil gener sharehold valu even worst-
case scenario outcom believ speak knight dilig approach capit
januari knight obtain exclus distribut right synergi strip corpor
product canada select intern market part licens agreement
synergi sign conjunct secur loan synergi famili includ consum
product dietary/weight loss supplement flat tummi tea focusfactor dietari
supplement claim improv brain health approv health canada natur
health product octob
mention gener take stanc natur product homeopath
medicin lack rigor clinic data typic associ regul rx product
typic highli skeptic claim associ product associ
commerci longev product tend promot sensit reli direct
consum advertis variou outlet social media look forward
believ product materi contribut knight top line evolv robust
commerci pipelin rx product rather urg investor view product free
kicker obtain conjunct strateg lend activ model current assum
knight gener approxim mln revenu synergi famili product
howev lack confid longev revenu line item
interest incom capit
unlik major recent canadian specialti pharmaceut compani subscrib
pharma roll-up model acquir legaci asset perform life cycl manag knight
favour posit pigeon-hol multipl accret game
impetu knight consumm next acquisit order obscur
underwhelm perform former acquisit replac at-risk sourc cash flow
view afford knight opportun bide time order make well-research
meaning capit deploy provid protect cost capit knight opt
exercis extrem disciplin product-acquisit front market favour seller
buyer knight enter number high-interest secur lend agreement gener
strong irr strategi expect continu pursu price realign
expect suggest strategi view upon favour investor
commun cycl turn knight one well-posit compani
capit opportun expos investor rel minimum downsid risk
date knight deploy mln lend strategi averag interest rate
furthermor mani case knight negoti addit consider includ product
right equiti kicker date knight secur right greater product
secur lend strategi march knight outstand loan balanc
mln review knight lend transact date exhibit
canada research page
exhibit overview knight strateg loan
datecompanyamount warrant acquir mln pref share default knight took ownership asset june subsequ divest us right neuragen synergi strip corp minimum aggreg consider warrant acquir benefici interest apicorepaid full gener mln share sold gross proce mlnpaid full gener irr excess strip pend targetsissu equiti receiv year warrant mln share cost plu focusfactor synergi brand gud mln issu decreas matur equiti mln warrant flat tummi tea urgentrx mln issu matur may convert anytim common share warrant exercis price per common medic equitypurchas mln mln offer sub receipt gud exclus distributor tulsa-pro system canada initi bono targetsquebec isra distribut right rang flexiseq sequaderma productsloan assign gener irr solut pend equiti financ targetssecur project revenu stream touchscreen terminalscurr provid mln equiti commitmentright pipelin gud convert per shareissu mln warrant exercis pain drug right gud option develop product gud equityright current futur product gud territori cdn subject condit acquir crescita mln paid date equityright futur product gud territoriesprepaid mln irr date companyin sourc currenc canadian knight inc
canada research page
knight embark uniqu long-term strategi invest mln proven life scienc
fund order gener lp return strateg obtain preferenti access
innov pharmaceut product around world canadian market
novel strategi canada appear without preced exampl
similar strategi employ domain associ rusnano russian invest
group partner manner invest made domain compani result
russian product right novamedica pharmaceut compani control rusnano
exhibit illustr knight long-term licens strategi
date knight commit mln mln remain fund
mln earmark invest strategi exhibit invest long-term
orient knight expect dollar invest fund gener dollar
annual revenu futur product right acquir relationship establish
fund compani addit return princip date knight invest
strategi led licens iluvien alimera domain partner ix earli investor
alimera led licens agreement advaxi portfolio product
canada sector investor advaxi
acknowledg unorthodox strategi howev believ even knight
success secur right one potenti blockbust asset hundr asset
visibl prove success strategi refer paladin
top sell asset direct result paladin long-term horizon
canada research page
septemb knight offici establish rest-of-world global footprint
acquisit strateg interest medison biotech ltd isra specialti pharmaceut
compani consider given equiti interest amount mln common
share knight includ conting consider mln settl
found medison current israel fourth-largest healthcar compani rank
prescript volum preced roch janssen novarti approxim
employe time transact medison boast year profit growth
compound-annual-growth-rate exhibit
exhibit medison revenu ni mln
time transact knight disclos medison portfolio consist
product licens approxim high-profil global healthcar compani
therapeut area largest revenu contributor medic specialti small
number physician drive larg volum script neurolog diseas
oncology/endocrinolog accord knight approxim medison
product portfolio current represent canada manag
believ may opportun leverag relationship medison could potenti
facilit introduct variou vendor seek canadian partner product
addit isra footprint medison maintain wholli own subsidiari establish
headquart bucharest romania current market leader rank
prescript volum knight gain rest world right number product
pipelin medison repres attract partner local market expertis variou
middl eastern eastern european jurisdict fact knight alreadi demonstr
valu partnership licens isra right movantik medison
march knight receiv dividend medison total mln
datemanag entityfundamount fund aumdevelop incnemo blnlate stage small capit partnersforbion capit fund mln mlnall clinic capitalterali capit innov fund lp terali mlnvcap fund associ domain partner ix domain mlnearli stagenorth ventur sanderl ventur vii mlnearli stagenorth partner llcharbourvest canada growth fund blnvcap fund inc nemo blnlate stage small capit life sciencetvm life scienc ventur blnvcap fund capit advisorsbloom burton lend mlnemerg capitalgenesi ventur mlnn/aall clinic stagesglob knight therapeut inc
canada research page
p/bvp best captur knight focu build sharehold equiti
initi knight outperform recommend per
share target price would typic valu specialti pharmaceut compani util
either dcf valuat methodolog forward ebitda multipl believ neither approach
accur captur inher valu knight current early-stag oper strategi
grow cash balanc particularli true present major knight earn
date gener interest incom loan receiv well uniqu invest
tactic furthermor would lack confid assumpt make present around
time futur debt issuanc product launch opt util price
book valu per share multipl valuat methodolog believ precis
repres current valu knight grow asset base specif valu knight
p/bvp repres discount north american specialti comp
current trade averag exhibit multipl result valu
per share round exhibit provid sensit analysi
around multipl exhibit
markettevdebt /compani namepricecap canadian spec pharmabiosy intern us spec pharmaakorn pharma public limit public limit compani american mln dilut epsev/ebitdap/ec mln except per book share bvpsp/bvp multipl canada research page
fiscal ye dec except gener properti intang exchang expens -- -- -- -- interest sale intang asset -- -- -- -- net acquisit -- -- -- -- net loss settlement loan -- -- -- -- impair net incom tax tax incom averag s/o fulli per share fulli knight therapeut inc
canada research page
fiscal ye dec except tax credit current tax current asset held inc tax sharehold equitycurr liabil account payabl pay rltd parti -- -- -- -- loan pay rltd parti -- -- -- -- incom tax balanc current incom tax equiti share comp inc earn sharehold liabil share canada research page
fiscal ye dec except activitiesnet item defer incom tax compens product right -- -- -- -- deprec properti intang cur fin ass net loss foreign exch non-cash wc rel op activitiespurch mark dispos mark curr fin loan deb repay loan invest sale invest activitiesnet proc share purchas option purchas fin dec equival equiv begin foreign exchang equiv end knight therapeut inc
canada research page
appendix manag board director
prior establish knight therapeut mr goodman co-found paladin lab inc
purchas bln novemb prior co-found
paladin mr goodman consult bain compani also work brand
manag procter gambl mr goodman hold ba great distinct mcgill
univers london school econom class honour addit hold
llb mcgill univers mr goodman member bar new york
massachusett accredit pharmaceut manufactur repres season
lectur pharmaceut entrepreneurship mcgill univers mr goodman name
quebec entrepreneur year life scienc ernst young mr
goodman leadership invest paladin found worth approxim
ms sakhia join knight presid august assum addit respons
cfo octob prior knight ms sakhia serv cfo paladin
paladin ms sakhia respons financ oper human resourc investor
relat function employ paladin ms sakhia instrument
execut in-licens acquisit transact canadian intern pharmaceut
product busi addit ms sakhia led sever strateg lend
transact well equiti round tsx complet sale paladin endo
billion ms sakhia hold bachelor commerc degre
mcgill univers also charter profession account ms sakhia serv
board crescita therapeut inc profound medic corpor
addit ms sakhia serv board montreal societi prevent cruelti
anim intern advisori board mcgill desautel faculti manag
independ board member mcgill univers health center
prior join knight ms khouri work novarti pharma seven year
held multipl posit within global busi develop licens team basel
switzerland join novarti work busi develop paladin lab role
increas respons ms khouri hold bsc biochemistri mcgill univers
mba univers ottawa
mr gale found partner signet healthcar partner current chairman
board alpex pharma telig inc also serv board director
spepharm ag bionpharma inc corerx inc leon nanodrug gmbh chr olesen synthesi
a/ prior signet mr gale work gruntal co llc head princip invest
activ invest bank prior join gruntal work insur co
gruntal parent earlier career mr gale senior invest banker hutton
co mr gale hold univers chicago mr gale board paladin
lab
canada research page
thesi heavili depend confid mr goodman continu abil execut
per histor preced unabl oper knight effect paladin
scenario aris would demand step ceo would materi
impact outlook howev said believ worth note mr goodman date
assembl outstand team support led jeffrey kadanoff khouri
could somewhat mitig risk
impavido current gener threat given buyer impavido typic
develop nation believ much safeti afford brand loyalti
anticip impavido sale market ex-u face pressur howev given impavido
royalti becom immateri knight top line develop busi find
mr goodman current largest sharehold knight own compani
possibl interest may diverg sharehold point
knight current util barbado corpor tax structur one subsidiari
chang relev tax law futur may impair knight tax strategi
paladin success spur abund new canadian specialti pharmaceut
compani result demand canadian right pharmaceut asset histor
high acquisit price multipl expand respons guarante
market inde shift result valuat correct knight may forc
amend strategi acquir product price multipl high end histor preced
materi impact futur forecast valuat due slower growth rate reduc
part knight strategi includ lend capit life scienc compani knight
loan fulli secur possibl scenario manifest knight unabl
recuper invest scenario would neg impact compani valuat
furthermor would cast doubt abil structur similar transact futur
canada research page
note price recent close indic exchang may us disclosur section rate definit
